Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
End-stage Kidney Disease
Optimizing Kidney Transplant Informed Consent
The objective of this study is to evaluate kidney transplant candidates' comprehension about increased risk donor kidneys necessary for informed consent.
- Trial name
- NCT01859884
- Testing
- Inform Me: web-based education tool
- Where
- 2 sites in United States
- Volunteers
- 288 people
- Sponsor
- Northwestern University
Chronic Hepatitis C
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.
- Trial name
- NCT01790100
- Testing
- VX-135, Ribavirin
- Where
- Moldova
- Volunteers
- 20 people
- Sponsor
- Alios Biopharma Inc.
Hepatitis C
Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.
This study aims to evaluate the possible antifibrotic effect of zinc sulphate in chronic HCV patient receiving direct acting anti-viral therapy
- Trial name
- NCT05465434
- Testing
- Zinc Supplement
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Chronic Hepatitis C
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
The purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis C patients who have never before received treatment.
- Trial name
- VISER2 (NCT00093093)
- Testing
- Viramidine, Ribavirin, pegylated interferon alfa-2a
- Where
- 100 sites in United States, Argentina and 10 more
- Volunteers
- 900 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis C
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan.
- Trial name
- NCT00200343
- Testing
- Ursodeoxycholic acid 150mg / day, Ursodeoxycholic acid 600mg / day, Ursodeoxycholic acid 900mg / day
- Where
- Japan
- Volunteers
- 596 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients
Hepatitis C infection is a major public health problem with nearly 175 million infected individuals worldwide. Although cure is possible, only 20-40% of patients spontaneously resolve infection and 40-80% of chronically infected…
- Trial name
- NCT01567540
- Testing
- Sitagliptin
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Genotype 1 Chronic Hepatitis C
Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C
The purpose of this study is to determine the effectiveness, safety and tolerability of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) in…
- Trial name
- NCT01498068
- Testing
- Telaprevir, Pegylated-interferon-alfa-2a, Ribavirin
- Where
- 5 sites in Russia
- Volunteers
- 36 people
- Sponsor
- Janssen-Cilag International NV
Chronic Hepatitis C
A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients
A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 in Healthy Volunteers and to…
- Trial name
- NCT02617615
- Testing
- MB-110
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Microbio Co Ltd
Chronic Hepatitis C
Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir
The purpose of the study is to 1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after…
- Trial name
- GENUPI (NCT01577069)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Association HGE CHU Bordeaux Sud
Chronic Hepatitis C (CHC)
A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
This is a study designed to compare the safety and efficacy of 3 different doses of grazoprevir (MK-5172) combined with pegylated interferon alfa-2b (PEG-IFN) and ribavirin (RBV) in treatment-naïve participants with genotype 1…
- Trial name
- NCT01710501
- Testing
- Grazoprevir, pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 87 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- LIFE-C (NCT02615145)
- Volunteers
- 472 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus Infection
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
The main objective of this study is to assess whether a recently-developed bioassay for the protein FGL2 can be used to predict the progression and/or response to treatment of Hepatitis C Virus disease in patients with chronic…
- Trial name
- NCT00606528
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hepatitis C
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
- Trial name
- NCT03402165
- Testing
- Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
- Where
- Egypt
- Volunteers
- 1,200 people
- Sponsor
- Sherief Abd-Elsalam
Hepatitis C, Chronic, Hepatitis C
Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
The objective of the study is to assess the safety and efficacy of Intron A (3 Mio I.E./m2, 3 times per week) and Rebetol (15 mg/kg/day) in children aged 3 to 17, treated in common medical practice at 10 sites in Germany.
- Trial name
- NCT00727077
- Testing
- IntronA (interferon alfa-2b; SCH 30500), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepatitis C (CHC) genotype 4 infection who…
- Trial name
- START 4 (NCT01606800)
- Testing
- PEG-IFN alfa-2b, ribavirin
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections, Sexually Transmitted Infection
User-friendly HIV Testing and Counseling Services
Multicenter cohort study of individuals reporting behavioral risks of HIV acquisition, recruited among those presenting for testing for HIV and other sexually transmitted infections.
- Conditions
- HIV Infections, Sexually Transmitted Infection, Hepatitis B, Chronic, Hepatitis C
- Trial name
- NCT04585165
- Where
- 6 sites in Thailand
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
This is a two-part study of grazoprevir (MK-5172) + elbasvir (MK-8742) in Japanese participants with chronic hepatitis C virus (HCV) genotype 1 (GT1).
- Trial name
- NCT02203149
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 399 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, HIV Infections
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha…
- Conditions
- Hepatitis C, HIV Infections, COINFECTION
- Trial name
- BOC-HIV (NCT01718301)
- Testing
- boceprevir, Ribavirin, Peginterferon alfa-2a
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Anna Cruceta
Chronic Hepatitis C Infection
Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects
The study is designed to test the hypothesis that the addition of a protease inhibitor to dual NS5a-NS5B nucleoside prodrug analog will enhance antiviral efficacy and hence shorten the treatment duration to 3 weeks.
- Trial name
- NCT02470858
- Testing
- LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Humanity and Health Research Centre